This is a commercial channel expansion with no disclosed economics, making it a low-conviction signal. Monitor for follow-on VA adoption announcements or procurement orders to validate revenue potential. Without financial terms, the market impact is likely muted unless tangible revenue materializes in subsequent quarters.
Price Chart
Executive Summary
bioAffinity Technologies announced a nationwide federal healthcare distribution agreement for its CyPath Lung diagnostic test with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business. The agreement provides access to government procurement channels including the VA, but no financial terms, revenue guidance, or minimum purchase commitments were disclosed.
Key Facts
- Entered distribution agreement with AvMEDICAL for CyPath Lung test on August 18, 2026
- AvMEDICAL is a Service-Disabled Veteran-Owned Small Business with access to government procurement channels
- Agreement covers federal healthcare agencies including VA medical centers nationwide
- No financial terms, upfront payments, minimum commitments, or revenue guidance disclosed
- AvMEDICAL's sales team will market CyPath Lung to federal customers
- Company has $3M market cap and faces Nasdaq listing compliance risks
Financial Impact
No financial figures disclosed — deal value, upfront payments, and revenue expectations are absent from the filing
Risk Factors
- No financial terms disclosed — the agreement may be non-exclusive or low-volume
- Reliance on third-party distributor for market access with uncertain adoption by government providers
- Company has limited operating history, history of losses, and Nasdaq compliance risk
- Government procurement cycles are slow and unpredictable
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (BIAF) — Batch item 1 | 0001493152-26-038897 |
| Exhibit: ex99-1.htm | 0001493152-26-038897 |
| Document: 0001493152-26-038897-index-headers.html | 0001493152-26-038897 |
| Document: 0001493152-26-038897-index.html | 0001493152-26-038897 |
| Document: 0001493152-26-038897.txt | 0001493152-26-038897 |
| 8-K Filing (BIAF) — Batch item 6 | 0001493152-26-038897 |
| Exhibit: ex99-1.htm | 0001493152-26-038897 |
| Document: 0001493152-26-038897-index-headers.html | 0001493152-26-038897 |
| Document: 0001493152-26-038897-index.html | 0001493152-26-038897 |
| Document: 0001493152-26-038897.txt | 0001493152-26-038897 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | DEF 14A | $2.83 | awaiting T+60 | — | $2.96 (+4.59%) |
Oct 15, 2026 12d ago | 8-K | $3.96 | awaiting T+60 | — | $2.96 (−25.25%) |
Oct 13, 2026 14d ago | 8-K | $3.63 | awaiting T+60 | — | $2.96 (−18.34%) |
Oct 9, 2026 18d ago | 8-K | $3.90 | awaiting T+60 | — | $2.96 (+24.10%) |
Oct 9, 2026 18d ago | 424B5 | $4.73 | awaiting T+60 | — | $2.96 (+37.35%) |
Oct 9, 2026 18d ago | 424B5 | $4.73 | awaiting T+60 | — | $2.96 (−37.35%) |
Oct 8, 2026 19d ago | 8-K | $5.64 | awaiting T+60 | — | $2.96 (−47.52%) |
Oct 6, 2026 21d ago | 8-K | $6.06 | awaiting T+60 | — | $2.96 (−51.16%) |
Sep 30, 2026 27d ago | 8-K | $6.56 | awaiting T+60 | — | $2.96 (−54.88%) |
Sep 22, 2026 5w ago | 8-K | $8.56 | awaiting T+60 | — | $2.96 (−65.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers